Phase II Trial of Nivolumab and Ipilimumab in dMMR Recurrent Endometrial Carcinoma
A phase II trial is testing the efficacy of nivolumab combined with ipilimumab versus nivolumab alone in patients with dMMR recurrent endometrial carcinoma.
Phase II
dMMR recurrent endometrial carcinoma
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase II trial of nivolumab combined with ipilimumab in dMMR recurrent endometrial carcinoma could significantly alter treatment protocols in this niche oncology segment. Positive trial outcomes may enhance competitive positioning for companies involved in immunotherapy, necessitating close monitoring of results.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results and overall survival data from the trial.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.